Latest William K. Oh Stories
A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.
LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Phase III Trial Now Recruiting Patients SANTA ROSA, Calif., April 15, 2014 /PRNewswire/ -- A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now
ResearchMoz.us include new market research report "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" to its huge
-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan.
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy.
- The parings of haberdine; also, any kind of fragments.